Bringing cellular engineering expertise to TERMIS 2025

Vienna, Austria: – Innovative biotech manufacturer Evercyte will contribute to the scientific agenda of the upcoming TERMIS EU Congress in the German city of Freiburg.

Evercyte Chief Operating Officer and Chief Scientific Officer Dr Regina Grillari have been selected to address the final day of the conference as part of the session on Extracellular Vesicles for Therapeutic Applications.

Cell factories

Her presentation on ‘Telomerized MSCs of various tissues and donors: designer cell factories for standardizable and scalable production of clinical-grade extracellular vesicles’ will explain the advantages of the Evercyte approach to creating ‘cell factory’ panels of telomerized GMP-ready cells that retain their essential human properties over extended life spans. (Friday, 23 May, 1220-1228 CEST, Room K11).

Dr. Grillari will also cover the relevance of Evercyte’s cell and EV engineering to the EVscale™ consortium developing a one-stop solution for EV production, scale up and characterization.

EV vision

Regina Grillari commented: “Our ultimate EVscale™ vision is to provide an innovative one-stop shop and end-to-end platform for scalable and efficient manufacturing of extracellular vesicles from MSCs that will allow customers to tailor projects from cell sourcing to basic EV characterization, and from EV manufacturing to linking EV biological functions to RNA and protein EV components.”

“Cells can then be adapted to tailored and scalable EV production using a fully controllable bioreactor,” she explained.

About Evercyte GmbH

Evercyte is the leading provider of immortalized human primary-like cells (telomerized cells) as well as novel cell lines for production of extracellular vesicles and is the partner of choice for innovative cell-based assays in the field of pharma, biotech, or cosmetic industries.

The core technology used for the establishment of these highly relevant human cell lines relies on the reactivation of the human telomerase enzyme. Besides customer-tailored cell line development as a one-stop shop, Evercyte is steadily expanding its catalogue of readily available cell lines for production of extracellular vesicles from mesenchymal stromal cells using different tissues including adipose tissue, bone marrow, placenta, amnion or dental pulp.

By providing native extracellular vesicles from mesenchymal stromal cells, Evercyte will make a significant contribution to the development of new therapeutic approaches. Additionally, Evercyte will promote its platform technology for the generation of recombinant EVs e.g. tissue targeting and targeted drug delivery.

Founded in 2011, the Vienna-based company successfully pioneered the development of tools and know-how necessary for the establishment of standardized high-throughput in vitro bioassays as well as relevant cell models and cell factories.

Learn more at: http://www.evercyte.com

About TERMIS EU Congress 2025

The TERMIS EU Congress 2025 is the annual meeting of the European chapter of the Tissue Engineering and Regenerative Medicine International Society (TERMIS), the organisation founded in 2005 as the merger of former European Tissue Engineering Society (ETES) and the US-based Tissue Engineering Society International, Inc. (TESI).

The TERMIS mission is to provide a global organization that would link researchers in the tissue engineering field worldwide.

The 2025 TERMIS EU Congress is a five-day event, opening May 19, 2025, at the Messe Freiburg Convention Center in the University city of Freiburg, in Western Germany.

Themed “Shaping the Future by Connecting Scientific Diversity”, the 2025 Congress will emphasize interdisciplinary collaboration between laboratory research and clinical application, featuring plenary lectures from leading international experts, scientific sessions   on topics such as biomaterials, stem cell therapy, bioprinting, and gene therapy and workshops to demonstrate clinical use of biomaterials and other innovations.

The event is organised by TERMIS with further information at: https://eu2025.termis.org

Resources

Click on Evercyte Cell Factories for EVs to learn more.
Click on Evercyte off-the shelf-EVs for further information.